Last reviewed · How we verify
pecazine
pecazine is a drug. It is currently in unknown development for Allergic conjunctivitis, Allergic rhinitis, Angioedema.
At a glance
| Generic name | pecazine |
|---|---|
| Target | 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A |
| Therapeutic area | Dermatology |
| Phase | unknown |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Angioedema
- Dermatographic urticaria
- General anesthesia
- Itching of skin
- Nasal congestion
- Nasal discharge
- Sneezing
- Urticaria
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pecazine CI brief — competitive landscape report
- pecazine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about pecazine
What is pecazine?
pecazine is a pharmaceutical drug, indicated for Allergic conjunctivitis, Allergic rhinitis, Angioedema.
What is pecazine used for?
pecazine is indicated for Allergic conjunctivitis, Allergic rhinitis, Angioedema, Dermatographic urticaria, General anesthesia.
What development phase is pecazine in?
pecazine is in unknown.
What does pecazine target?
pecazine targets 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A.
Related
- Target: All drugs targeting 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Angioedema
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing